December 29, 2014 4:08 AM ET

Healthcare Equipment and Supplies

Company Overview of InSightec Ltd.

Company Overview

InSightec Ltd. develops and markets non-invasive surgery systems that destroy tumors inside the body without the need for open surgery. The company specializes in ExAblate, a MR guided focused ultrasound technology. It provides ExAblate O.R., a platform for treating body applications that offers research treatment options for a multitude of clinical indications, such as uterine fibroids and adenomyosis, pain palliation of bone metastases, breast cancer, prostate cancer, and various other indications; and ExAblate Neuro, a system for the treatment of essential tremor, Parkinson’s, and neuropathic pain. The company was founded in 1999 and is headquartered in Tirat Carmel, Israel with additiona...

5 Nahum Heth Street

POB 2059

Tirat Carmel,  39120

Israel

Founded in 1999

Phone:

972 4 813 1313

Fax:

972 4 813 1322

Key Executives for InSightec Ltd.

Founder and Chief Executive Officer
President and Chief Commercial Officer
Executive Chairman of the Board
Age: 53
Chief Financial Officer and Vice President
Vice President of Operations and Quality
Compensation as of Fiscal Year 2014.

InSightec Ltd. Key Developments

INSIGHTEC Appoints Maurice R. Ferré as Executive Chairman of the Board

INSIGHTEC announced Dr. Maurice R. Ferré, a seasoned medical device executive, will join the INSIGHTEC leadership team as its newly appointed Executive Chairman of the Board of Directors. Dr. Ferré most recently served as CEO and Chairman of MAKO Surgical Corp.

Elbit Imaging Ltd. Announces InSightec Wins Approval in Japan for Treatment of Pain Palliation Caused by Bone Metastases and for Advanced Treatment of Uterine Fibroids

Elbit Imaging Ltd. announced that it was informed by InSightec Ltd. (InSightec) that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved InSightec's MR-guided Focused Ultrasound (MRgFUS) system for the treatment of pain palliation caused by bone metastases and advanced treatment for women with uterine fibroids. As a result, InSightec may expand its product portfolio for the Japanese market. MHLW has also approved the advanced treatment for women with uterine fibroids. This advanced treatment provides additional treatment options and shortens treatment time, allowing physicians to better monitor the procedure.

Robert Sigal Joins InSightec, Ltd. as President and Chief Commercial Officer

InSightec Ltd. announced that Robert Sigal, MD, PhD, to be joining InSightec as President and Chief Commercial Officer as of October 13, 2013. He will be responsible for all the commercial aspects of InSightec reporting to Dr. Kobi Vortman, CEO and Founder of InSightec Ltd. Robert joins InSightec from GE Healthcare where he served most recently as the General Manager of GE Healthcare France.

Similar Private Companies By Industry

Company Name Region
V Wave Ltd. Middle East/Africa
ProstaPlant Urology Systems Ltd. Middle East/Africa
Surgical Structure Ltd. Middle East/Africa
Bioscan Technologies, Ltd. Middle East/Africa
WaisMed Ltd. Middle East/Africa

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 6, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact InSightec Ltd., please visit www.insightec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.